Groundbreaking eye treatment trial offers hope for rare genetic vision loss in children
NCT ID NCT07269665
Summary
This first-in-human study aims to test the safety and find the right dose of a new treatment called AXV-101 for children aged 4-17 with Bardet-Biedl syndrome type 1 (BBS1) who have early retinal degeneration. Researchers will give a single dose to one eye and closely monitor both eyes for five years to see if the treatment is safe and how it behaves in the body. The main goal is to understand if this potential treatment can be safely given to help slow down vision loss in this rare genetic condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINAL DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moorfields Eye Hospital
London, EC1V 2PD, United Kingdom
Conditions
Explore the condition pages connected to this study.